Phathom Pharmaceuticals, Inc. - PHAT Business Value to Revenue

Official company branding of Phathom Pharmaceuticals, Inc. (PHAT)

The EV/Sales ratio for Phathom Pharmaceuticals (PHAT) on GURU.Markets reflects market sentiment, with the metric holding at 2851.64. This trend is driven by business protection via unique patents and strict FDA control. Phathom Pharmaceuticals (PHAT) is expanding its portfolio with innovations for the mass GI segment, while rapid growth in US prescription sales provides powerful operating leverage and optimization of marketing expenses.

Phathom Pharmaceuticals (PHAT): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

PHAT (Phathom Pharmaceuticals, Inc.): analytical breakdowns and indicator data

- stock price and consensus target price:
- issuer market value details:
Fundamental company valuation:Phathom Pharmaceuticals PHAT
Product sample of phathompharma.com

Phathom Pharmaceuticals (PHAT) maintains strong pricing power driven by the introduction of an innovative GI therapy drug. This metric compares the total enterprise value to annual revenue, excluding the impact of leverage. It allows for an assessment of the market premium paid per unit of revenue without distortions from debt load. A critical overvaluation of this ratio signals a risk of price correction. The trend of the EV to total revenue multiple reflects the current investment attractiveness of the company.